{"product_id":"eypt-vrio-analysis","title":"EyePoint Pharmaceuticals, Inc. (EYPT): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eWhat truly separates EyePoint Pharmaceuticals, Inc. (EYPT) from the pack? This VRIO analysis cuts straight to the core, dissecting whether its resources possess the necessary Value, Rarity, Inimitability, and Organization to secure a lasting competitive edge. Explore the distilled findings within \u0026amp;O4\u0026amp; now to uncover the definitive strengths and weaknesses that shape EyePoint Pharmaceuticals, Inc. (EYPT)'s strategic future.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eEyePoint Pharmaceuticals, Inc. (EYPT) - VRIO Analysis: 1. Proprietary Durasert E™ Sustained Drug Delivery Technology\n\u003c\/h2\u003e\n\n\u003cp\u003eYou're looking at the core engine of EyePoint Pharmaceuticals, Inc.'s future value proposition: the Durasert E™ technology. Forget the jargon for a second; this is about keeping medicine in the eye where it needs to be for longer, which is a massive win for patients dealing with chronic conditions like wet AMD.\u003c\/p\u003e\n\n\u003cp\u003eThe technology itself, a bioerodible version of their proven Durasert® platform, is designed to deliver drugs like vorolanib with an initial burst, followed by a near-constant zero-order kinetic release for up to \u003cstrong\u003enine months\u003c\/strong\u003e. This directly attacks the market driver of patient burden, which currently demands frequent, often monthly, injections. EyePoint is aiming for an every-six-month dosing regimen for wet AMD, a clear step-change in care.\u003c\/p\u003e\n\n\u003ch3\u003eVRIO Assessment of Durasert E™ Platform\u003c\/h3\u003e\n\u003cp\u003eHere’s the quick math on how this platform stacks up against competitors using the VRIO framework:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eDimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eSupporting Detail\/Implication\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (V)\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eAddresses patient burden by enabling sustained delivery (up to \u003cstrong\u003enine months\u003c\/strong\u003e). Supports lead candidate DURAVYU™ in Phase 3 for wet AMD and DME.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity (R)\u003c\/td\u003e\n\u003ctd\u003eRelatively Unique\u003c\/td\u003e\n\u003ctd\u003eThe specific, proven, bioerodible formulation in the ophthalmic space is not common. DURAVYU is the only TKI in development for DME using this technology.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability (I)\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eReplication is difficult due to the specific, proven formulation and successful application in late-stage products. Core concept is known, but execution is hard.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (O)\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eThe entire pipeline, including DURAVYU™, is built around leveraging this platform, showing strong internal alignment. The company secured \u003cstrong\u003e$204 million\u003c\/strong\u003e in cash as of September 30, 2025, plus a recent \u003cstrong\u003e$162 million\u003c\/strong\u003e raise in October 2025, to fund operations into \u003cstrong\u003eQ4 2027\u003c\/strong\u003e, well past key data readouts.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained\u003c\/td\u003e\n\u003ctd\u003eThe platform is the core, hard-to-replicate asset underpinning their entire strategy, which has already treated tens of thousands of eyes across four approved drugs.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eStrategic Alignment and Financial Backing\u003c\/h3\u003e\n\u003cp\u003eThe organization is definitely structured to exploit this asset. They aren't just dabbling; the entire focus is on advancing DURAVYU™, which combines vorolanib with Durasert E™. This focus is backed by recent capital; after reporting a net loss of \u003cstrong\u003e$59.7 million\u003c\/strong\u003e for Q3 2025, EyePoint raised an additional \u003cstrong\u003e$162 million\u003c\/strong\u003e in October 2025. What this estimate hides is that this financing was specifically intended to fully fund the DME pivotal program and extend the cash runway into \u003cstrong\u003eQ4 2027\u003c\/strong\u003e, giving them time past the anticipated mid-2026 topline data for the wet AMD trials.\u003c\/p\u003e\n\n\u003cp\u003eThe platform's success is also evidenced by its history. EyePoint has four FDA-approved drugs over three decades that utilized their innovation, treating tens of thousands of eyes. This track record helps de-risk the Durasert E™ component for regulators and physicians, even as DURAVYU™ itself is still investigational.\u003c\/p\u003e\n\n\u003cp\u003eHere are the key strategic implications of this technology:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003ePipeline Anchor:\u003c\/strong\u003e Durasert E™ is the foundation for DURAVYU™ in wet AMD and DME.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Position:\u003c\/strong\u003e Aims to be first to file\/market among investigational six-month sustained release programs for wet AMD.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOperational Readiness:\u003c\/strong\u003e The Northbridge, MA commercial manufacturing facility is on line with DURAVYU registration batches underway.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eEyePoint Pharmaceuticals, Inc. (EYPT) - VRIO Analysis: 2. DURAVYU™ (Vorolanib Insert) Clinical Data Package (Phase 3)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides robust safety and efficacy data in the two largest retinal markets (wet AMD and DME), de-risking future regulatory submissions and commercial adoption.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many companies have Phase 2 data, but having two fully enrolled Phase 3 trials (LUGANO\/LUCIA) in wet AMD by late 2025 is a strong position.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. Competitors can run trials, but they cannot replicate EyePoint’s existing, favorable safety profile in over \u003cstrong\u003e190\u003c\/strong\u003e patients treated to date across four clinical studies.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The company is executing flawlessly on trial enrollment, showing they can manage complex, global late-stage studies effectively.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Data ages; the advantage shifts to commercial execution once data is public, but the current de-risked status is a near-term win.\u003c\/p\u003e\n\u003cp\u003eThe clinical data package for DURAVYU™ is supported by prior Phase 2 data from the DAVIO 2 trial, which enrolled 160 patients, exceeding its original target of 144. Data from DAVIO 2 demonstrated that 63 per cent of eyes treated with Duravyu did not require supplemental aflibercept treatment for up to six months post-insertion. Furthermore, treatment burden was reduced by 80 per cent among trial participants compared to their pre-trial regimen.\u003c\/p\u003e\n\u003cp\u003eThe Phase 3 pivotal program consists of two identical, randomized, double-masked, aflibercept-controlled, noninferiority trials, LUGANO and LUCIA, developed in alignment with the FDA and EMA.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eTrial Parameter\u003c\/th\u003e\n\u003cth\u003eLUGANO \/ LUCIA (Phase 3)\u003c\/th\u003e\n\u003cth\u003eDAVIO 2 (Phase 2)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndication Evaluated\u003c\/td\u003e\n\u003ctd\u003eWet Age-Related Macular Degeneration (wet AMD)\u003c\/td\u003e\n\u003ctd\u003eWet AMD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnrollment Status\u003c\/td\u003e\n\u003ctd\u003eEnrollment Complete (LUGANO in May 2025; LUCIA completed enrollment)\u003c\/td\u003e\n\u003ctd\u003eEnrollment Complete\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproximate Patients Per Trial\u003c\/td\u003e\n\u003ctd\u003eOver 400 patients per trial\u003c\/td\u003e\n\u003ctd\u003e160 patients total\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Phase 3 Enrollment\u003c\/td\u003e\n\u003ctd\u003eOver 800 patients across both trials\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eControl Arm\u003c\/td\u003e\n\u003ctd\u003eOn-label aflibercept control\u003c\/td\u003e\n\u003ctd\u003eAflibercept control\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDosing Schedule Evaluated\u003c\/td\u003e\n\u003ctd\u003e6-month redosing over two-years\u003c\/td\u003e\n\u003ctd\u003eSix-month maintenance treatment evaluation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary Endpoint Assessment\u003c\/td\u003e\n\u003ctd\u003eAverage change in BCVA at weeks 52 and 56\u003c\/td\u003e\n\u003ctd\u003eImprovement in BCVA (Primary Endpoint Met)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Topline Data\u003c\/td\u003e\n\u003ctd\u003eMid-2026 (LUGANO), followed by LUCIA\u003c\/td\u003e\n\u003ctd\u003eQ4 2023 (Reported in March 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe trials are designed such that all patients are randomized on Day 1 and immediately begin treatment. The DURAVYU dose being evaluated is 2.7-mg.\u003c\/p\u003e\n\u003cp\u003eThe overall development program has supported the following statistical milestones:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDURAVYU has been evaluated in over 190 patients across four clinical trials to date.\u003c\/li\u003e\n\u003cli\u003eNo ocular or systemic serious adverse events related to the drug observed in the Phase 3 trials based on interim masked safety data.\u003c\/li\u003e\n\u003cli\u003eLUCIA trial enrolled and randomized over 400 patients in seven months.\u003c\/li\u003e\n\u003cli\u003eVorolanib is the most studied Tyrosine Kinase Inhibitor (TKI) in retinal disease.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eEyePoint Pharmaceuticals, Inc. (EYPT) - VRIO Analysis: 3. Robust Intellectual Property Portfolio for DURAVYU™\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Protects the drug (vorolanib) and the delivery system (Durasert E™), creating a barrier to entry for future competitors in the sustained-release space.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. A comprehensive patent estate covering both the active ingredient formulation and the delivery mechanism is crucial and not easily assembled.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Patents are legally protected barriers; imitation requires navigating around or waiting for expiration.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The company explicitly focuses on maintaining and expanding this portfolio, showing it’s a strategic priority.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Global Patents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e987\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGranted Patents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e536\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive Patents (Approximate Percentage)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMore than 41%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA Approved Products Utilizing Durasert Technology\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUtilizing Durasert technology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe strategic commitment to the IP and the underlying technology is evidenced by financial allocations supporting the pipeline protected by this portfolio:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOperating expenses for the full year ended December 31, 2024, totaled \u003cstrong\u003e$189.1 million\u003c\/strong\u003e versus $121.1 million in 2023, driven by Phase 3 trials for DURAVYU.\u003c\/li\u003e\n\u003cli\u003eOperating expenses for the third quarter ended September 30, 2024, included \u003cstrong\u003e$5.4 million\u003c\/strong\u003e in costs related to the DURAVYU™ Phase 3 clinical trials for wet AMD.\u003c\/li\u003e\n\u003cli\u003eCash and investments at December 31, 2024, were \u003cstrong\u003e$371 million\u003c\/strong\u003e, providing cash runway into \u003cstrong\u003e2027\u003c\/strong\u003e beyond topline DURAVYU Phase 3 wet AMD data expected in \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eDURAVYU combines the patent-protected vorolanib with proprietary Durasert E™ technology.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eEyePoint Pharmaceuticals, Inc. (EYPT) - VRIO Analysis: 4. Commercial-Ready cGMP Manufacturing Facility (Northbridge, MA)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Ensures control over supply chain quality and volume, crucial for commercial launch readiness and avoiding the common pitfall of manufacturing scale-up delays.\u003c\/p\u003e\n\u003cp\u003eThe facility is a 41,000-square-foot standalone site designed and constructed to meet U.S. FDA and European Medicines Agency (EMA) standards. It includes pharmaceutical production suites for clinical supply and commercial scale manufacturing of approved products, such as DURAVYU. The building is equipped with specialized mechanical systems, including an advanced water filtration system and a propane-fired electric generator capable of powering the building for four days in the event of an electrical outage.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eSpecification\u003c\/th\u003e\n\u003cth\u003eDetail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFacility Size\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e41,000 sq. ft.\u003c\/strong\u003e (Initial announcement: 40,000 sq. ft.)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance Standards\u003c\/td\u003e\n\u003ctd\u003ecGMP compliant for U.S. FDA and EMA standards\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduction Suites\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e10\u003c\/strong\u003e production suites\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClean Room Standard\u003c\/td\u003e\n\u003ctd\u003eBuilt to \u003cstrong\u003eISO 7\u003c\/strong\u003e clean room standards\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperational Status (as of Aug 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eDURAVYU registration batches underway\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many clinical-stage firms rely on third parties; having a 41,000 sq ft facility built to FDA\/EMA standards is a significant, tangible asset.\u003c\/p\u003e\n\u003cp\u003eThe facility includes specialized infrastructure such as:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePharmaceutical production suites for clinical supply and commercial scale manufacturing.\u003c\/li\u003e\n\u003cli\u003eChemistry and development laboratories and manufacturing support spaces.\u003c\/li\u003e\n\u003cli\u003eQuality Control and Quality Assurance (QC\/QA) functions and administrative spaces.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Building a cGMP facility is costly and takes years, but a competitor could contract a specialized CMO (Contract Manufacturing Organization). The construction timeline spanned from Spring 2023 to Summer 2024. EyePoint secured approximately $1.9 million in state and local tax incentives related to the facility.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. They are actively preparing for pre-approval inspection, showing operational readiness for scale. The facility is on line with DURAVYU registration batches underway as of the second quarter of 2025.\u003c\/p\u003e\n\u003cp\u003eKey organizational milestones related to the facility include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eExpected operational readiness in the second half of 2024.\u003c\/li\u003e\n\u003cli\u003eLease agreement with an initial term of 15 years and four months upon commencement.\u003c\/li\u003e\n\u003cli\u003eRent obligations commencing upon facility occupation in the second half of 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It’s a valuable asset now, but a competitor could secure capacity elsewhere, though perhaps not as integrated.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eEyePoint Pharmaceuticals, Inc. (EYPT) - VRIO Analysis: 5. Strong Financial Position (Cash Runway into Q4 2027)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides the necessary capital to fund all four Phase 3 trials through data readout without immediate pressure to raise capital under potentially unfavorable market terms.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While many biotechs struggle, EyePoint’s cash, cash equivalents, and marketable securities of \u003cstrong\u003e$204 million\u003c\/strong\u003e as of September 30, 2025, plus the \u003cstrong\u003e$162 million\u003c\/strong\u003e raised in net proceeds in October 2025, gives them a runway extending past the \u003cstrong\u003efourth quarter of 2027\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. Competitors cannot simply generate this cash balance without issuing equity or debt, which carries its own costs. The financing event in October 2025 secured gross proceeds of \u003cstrong\u003e$172.5 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. Management has successfully managed financing events to secure a long runway, demonstrating fiscal prudence. Operating expenses for the third quarter ended September 30, 2025, totaled \u003cstrong\u003e$63.0 million\u003c\/strong\u003e, which is covered by the secured capital.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Financial stability buys time, which is the ultimate competitive advantage in drug development.\u003c\/p\u003e\n\n\u003cp\u003eThe financial strength is directly linked to the advancement of the lead candidate, DURAVYU™, across its pivotal trials:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePhase 3 LUGANO trial randomized \u003cstrong\u003e432 patients\u003c\/strong\u003e in the U.S..\u003c\/li\u003e\n\u003cli\u003ePhase 3 LUCIA trial randomized over \u003cstrong\u003e400 patients\u003c\/strong\u003e in the U.S. and ex-U.S. sites.\u003c\/li\u003e\n\u003cli\u003eTopline 56-week data for LUGANO is on track for readout in mid-\u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eLUCIA topline data is anticipated to follow closely in the second half of \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eAmount \/ Period\u003c\/td\u003e\n\u003ctd\u003eDate Reference\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Marketable Securities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$204 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Proceeds from October Equity Financing\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$162 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOctober 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Proceeds from October Offering\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$172.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOctober 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Cash Runway End Date\u003c\/td\u003e\n\u003ctd\u003eInto the \u003cstrong\u003efourth quarter of 2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePost-October 2025 Financing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$63.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e($59.7 million)\u003c\/strong\u003e, or ($0.85) per share\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eEyePoint Pharmaceuticals, Inc. (EYPT) - VRIO Analysis: 6. Clinical Execution Track Record (Rapid Phase 3 Enrollment)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Demonstrates the market appeal of DURAVYU™ - physicians and patients are eager for a better treatment, leading to rapid enrollment in LUGANO and LUCIA trials in 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Rapid enrollment in large, pivotal trials is rare and signals strong physician acceptance of the underlying data\/concept.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. This is based on past performance and relationships; you can’t buy a track record of successful execution.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The speed of enrollment shows effective site selection and investigator engagement.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. This advantage fades once enrollment is complete, but it accelerated their timeline significantly.\u003c\/p\u003e\n\u003cp\u003eThe rapid enrollment across the two identical, randomized, double-masked, aflibercept-controlled, non-inferiority Phase 3 trials, LUGANO and LUCIA, for DURAVYU in wet Age-Related Macular Degeneration (wet AMD) provides quantitative evidence of strong clinical execution and market interest.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eLUGANO Trial\u003c\/td\u003e\n\u003ctd\u003eLUCIA Trial\u003c\/td\u003e\n\u003ctd\u003eCombined Program\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnrollment Completion Date\u003c\/td\u003e\n\u003ctd\u003eMay 2025\u003c\/td\u003e\n\u003ctd\u003eJuly 2025\u003c\/td\u003e\n\u003ctd\u003eEnrollment Complete as of July 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients Enrolled\/Randomized\u003c\/td\u003e\n\u003ctd\u003eOver 400 (specifically \u003cstrong\u003e432\u003c\/strong\u003e in the U.S.)\u003c\/td\u003e\n\u003ctd\u003eOver 400\u003c\/td\u003e\n\u003ctd\u003eOver 800 (as of July 2025); Over \u003cstrong\u003e900\u003c\/strong\u003e randomized (as of Q3 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnrollment Duration\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSeven months\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSeven months\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOne of the \u003cstrong\u003efastest enrolling\u003c\/strong\u003e Phase 3 pivotal programs for wet AMD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDosing Schedule Evaluated\u003c\/td\u003e\n\u003ctd colspan=\"2\"\u003e6-month redosing over two-years\u003c\/td\u003e\n\u003ctd\u003eUnique for sustained release wet AMD pivotal trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe organizational capability is further evidenced by the alignment with regulatory bodies and the safety profile established prior to and during these pivotal trials:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePhase 3 protocols received approval from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).\u003c\/li\u003e\n\u003cli\u003eDURAVYU was evaluated in over 190 patients across four clinical trials (including three Phase 2 trials) prior to Phase 3 completion, demonstrating a favorable safety profile with no DURAVYU related ocular or systemic Serious Adverse Events observed.\u003c\/li\u003e\n\u003cli\u003eThe Phase 2 DAVIO 2 trial supported the Phase 3 program and involved over 160 patients.\u003c\/li\u003e\n\u003cli\u003eInterim masked safety data from LUGANO and LUCIA was consistent with previous trials, leading an independent Data Safety Monitoring Committee (DSMC) to recommend continuation of the program as planned.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe financial commitment supporting this execution is reflected in the operating expenses related to these activities:\u003c\/p\u003e\n\u003cp\u003eOperating expenses for the third quarter ended September 30, 2025, totaled \u003cstrong\u003e$63.0 million\u003c\/strong\u003e, an increase from \u003cstrong\u003e$43.3 million\u003c\/strong\u003e in the prior year period, primarily driven by clinical trial costs related to the ongoing DURAVYU Phase 3 trials (LUGANO and LUCIA).\u003c\/p\u003e\n\u003cp\u003eAnticipated data read-out timelines further demonstrate the execution schedule:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTopline 56-week data for LUGANO expected in mid-2026.\u003c\/li\u003e\n\u003cli\u003eLUCIA topline data expected to follow LUGANO closely.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eEyePoint Pharmaceuticals, Inc. (EYPT) - VRIO Analysis: 7. Multi-Target Mechanism of Action (TKI + IL-6\/VEGF Inhibition)\n\u003c\/h2\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003e\u003cstrong\u003eDURAVYU™\u003c\/strong\u003e (vorolanib intravitreal insert) is positioned as a potential multi-mechanism of action (MOA) treatment by inhibiting both VEGF-mediated vascular permeability and IL-6 mediated inflammation.\u003c\/p\u003e\n\u003cp\u003eIL-6 is a pro-inflammatory cytokine observed at significantly higher levels in patients with DME and wet AMD compared to healthy individuals.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMechanism Target\u003c\/td\u003e\n\u003ctd\u003eInhibition Pathway\u003c\/td\u003e\n\u003ctd\u003ePreclinical Data\u003c\/td\u003e\n\u003ctd\u003ePhase 2 DME (VERONA) Supporting Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVEGF-mediated vascular permeability\u003c\/td\u003e\n\u003ctd\u003eInhibition of all VEGFRs\u003c\/td\u003e\n\u003ctd\u003eEstablished blockage\u003c\/td\u003e\n\u003ctd\u003eCST improved 75.9 microns vs. baseline; 74% more drying vs. aflibercept control.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIL-6 mediated inflammation\u003c\/td\u003e\n\u003ctd\u003eInhibition of all JAK receptors, particularly JAK-1\u003c\/td\u003e\n\u003ctd\u003eReduction in IL-6 activity of more than 50% in vitro.\u003c\/td\u003e\n\u003ctd\u003e73% of eyes in the 2.7mg arm were supplement-free up to week 24 vs. 50% in aflibercept control.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eThe sustained-release format delivering dual-target inhibition is a significant scientific differentiator.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDosing interval potential: At least six months after a single injection.\u003c\/li\u003e\n\u003cli\u003eWet AMD Phase 3 trials (LUGANO and LUCIA) evaluate every six-month re-dosing.\u003c\/li\u003e\n\u003cli\u003ePhase 2 DAVIO 2 (wet AMD) demonstrated treatment burden reduction of approximately 88% six months post-treatment, with over 80% of patients supplement-free or receiving only one supplemental anti-VEGF injection.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eReplicating this specific dual-action profile (TKI targeting VEGF\/JAK1 and IL-6) within a sustained-release format presents a major R\u0026amp;D hurdle for rivals.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDURAVYU™\u003c\/strong\u003e utilizes Durasert E™ technology, a proprietary and best-in-class bioerodible matrix designed to provide sustained release without free-floating drug particles.\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eThe company is actively integrating the multi-MOA potential into its commercial story, supported by regulatory alignment and Phase 3 progression.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePhase 3 DME program consists of two identical non-inferiority trials, “COMO” and “CAPRI,” each expected to enroll around 240 patients.\u003c\/li\u003e\n\u003cli\u003eFirst patient dosing in Phase 3 DME trials anticipated in Q1 2026.\u003c\/li\u003e\n\u003cli\u003ePhase 3 wet AMD trials (LUGANO and LUCIA) are fully enrolled; topline data for LUGANO anticipated in mid-2026.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eIf validated in Phase 3, this biological advantage is very difficult for competitors to overcome quickly.\u003c\/p\u003e\n\u003cp\u003eThe DME market is valued at a three-billion-dollar market and growing.\u003c\/p\u003e\n\u003cp\u003eFinancial backing: $172.5 million oversubscribed equity financing fully funds the DME pivotal program and extends cash runway into Q4 2027.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eEyePoint Pharmaceuticals, Inc. (EYPT) - VRIO Analysis: 8. First-to-Market Potential in Key Indications (Wet AMD\/DME)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Being first to market with a novel sustained-release therapy in multi-billion dollar indications like wet AMD allows for rapid market share capture and brand establishment.\u003c\/p\u003e\n\u003cp\u003eThe global Wet Age-Related Macular Degeneration (Wet AMD) market reached a value of \u003cstrong\u003eUSD 9,528.8 Million\u003c\/strong\u003e in 2024, projected to reach \u003cstrong\u003eUSD 18,317.5 Million\u003c\/strong\u003e by 2035. The overall Age-related Macular Degeneration Treatment Market was estimated at \u003cstrong\u003eUSD 12.06 billion\u003c\/strong\u003e in 2024. Diabetic Macular Edema (DME) impacts approximately \u003cstrong\u003e746,000\u003c\/strong\u003e individuals in the U.S. with diabetes aged $\\ge$ \u003cstrong\u003e40\u003c\/strong\u003e years.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eMarket Size Metric\u003c\/th\u003e\n\u003cth\u003eValue\/Projection\u003c\/th\u003e\n\u003cth\u003eSource Year\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWet AMD (Global)\u003c\/td\u003e\n\u003ctd\u003eMarket Value\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUSD 9,528.8 Million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWet AMD (Global)\u003c\/td\u003e\n\u003ctd\u003eProjected Market Value\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUSD 18,317.5 Million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2035\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAMD (Global)\u003c\/td\u003e\n\u003ctd\u003eMarket Value\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUSD 12.06 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDME (U.S. Patients)\u003c\/td\u003e\n\u003ctd\u003eEstimated Individuals\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e746,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eCurrent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. First-to-market is always sought after, but EyePoint is positioned to be first among investigational sustained release programs.\u003c\/p\u003e\n\u003cp\u003eDURAVYU is the \u003cstrong\u003eonly\u003c\/strong\u003e sustained release Tyrosine Kinase Inhibitor (TKI) being evaluated in DME.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. This is a time-based advantage; once someone files, the window closes for that specific 'first.'\u003c\/p\u003e\n\u003cp\u003eTopline data from the Phase 3 pivotal trials for DURAVYU in wet AMD (LUGANO and LUCIA) is expected in \u003cstrong\u003emid-2026\u003c\/strong\u003e. First patient dosing in the pivotal Phase 3 clinical trials for DME is anticipated in the \u003cstrong\u003efirst quarter of 2026\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The company’s entire development timeline is geared toward achieving this first-to-file\/first-to-market goal.\u003c\/p\u003e\n\u003cp\u003eThe company has cash runway extending into \u003cstrong\u003e2027\u003c\/strong\u003e beyond the topline DURAVYU Phase 3 wet AMD data expected in \u003cstrong\u003e2026\u003c\/strong\u003e. EyePoint has four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It’s a short-term commercial advantage that lasts until the next competitor launches.\u003c\/p\u003e\n\u003cp\u003eData from the Phase 2 VERONA DME trial demonstrated a treatment burden reduction of approximately \u003cstrong\u003e88%\u003c\/strong\u003e six months after treatment with DURAVYU, with over \u003cstrong\u003e80%\u003c\/strong\u003e of patients supplement-free or receiving only \u003cstrong\u003eone\u003c\/strong\u003e supplemental anti-VEGF injection. The Phase 2 DAVIO 2 trial in wet AMD demonstrated an \u003cstrong\u003e88%\u003c\/strong\u003e reduction in treatment burden at \u003cstrong\u003esix months\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDURAVYU Phase 3 wet AMD trials (LUGANO and LUCIA) are designed to evaluate \u003cstrong\u003e6-month\u003c\/strong\u003e re-dosing.\u003c\/li\u003e\n\u003cli\u003ePhase 2 DME trial showed sustained improvement with superior dosing intervals to standard of care.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eEyePoint Pharmaceuticals, Inc. (EYPT) - VRIO Analysis: 9. Specialized Ophthalmic Leadership Team\/Board Expertise\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Deep, specific expertise in retinal diseases and drug delivery minimizes strategic errors and enhances credibility with regulators and key opinion leaders (KOLs).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While many pharma companies have good leaders, a team with deep, specific ophthalmic focus is less common. The addition of Dr. Reginald J. Sanders, M.D., FASRS, in January 2025 bolsters this. Dr. Sanders is a charter inductee into the Retina Hall of Fame and helped build the Retina Group of Washington (RGW) to become the largest practice of retinal specialists in the United States.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. It takes years to build this level of domain-specific human capital and relationships. Dr. Sanders has authored over 50 papers, articles and presentations.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The team is executing on a highly specialized, complex development plan successfully, supported by a strong financial base.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Human capital and tacit knowledge are among the hardest resources to imitate.\u003c\/p\u003e\n\u003cp\u003eThe bedrock assets supporting this leadership execution are the Durasert E™ platform and the current financial position, which is significantly bolstered by recent capital raises.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial\/Pipeline Metric\u003c\/td\u003e\n\u003ctd\u003eValue\/Date\u003c\/td\u003e\n\u003ctd\u003eContext\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, Marketable Securities (as of 12\/31\/2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$371 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePre-October 2025 financing balance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, Marketable Securities (as of 9\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$204 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePost-October 2025 financing balance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Proceeds from October 2025 Equity Financing\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$162 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFrom underwritten public offering\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Cash Runway\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003eQ4 2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eBased on 9\/30\/2025 balance plus October financing proceeds\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDURAVYU™ Phase 3 Enrollment Completion (LUGANO \u0026amp; LUCIA)\u003c\/td\u003e\n\u003ctd\u003eExpected in \u003cstrong\u003e2H 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eWet AMD pivotal trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDURAVYU™ Phase 3 Topline Data (Wet AMD)\u003c\/td\u003e\n\u003ctd\u003eAnticipated in \u003cstrong\u003e2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey data points reinforcing the Durasert E™ platform's value and the team's execution:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDURAVYU™ is an investigational sustained delivery therapy utilizing the proprietary bioerodible \u003cstrong\u003eDurasert E™\u003c\/strong\u003e technology.\u003c\/li\u003e\n\u003cli\u003ePhase 2 VERONA trial in Diabetic Macular Edema (DME) demonstrated \u003cstrong\u003e16-week interim data\u003c\/strong\u003e showing \u003cstrong\u003eBCVA and CST improvement of +8.9 letters and -68 microns\u003c\/strong\u003e, respectively.\u003c\/li\u003e\n\u003cli\u003eThe LUGANO trial for wet AMD has enrolled approximately \u003cstrong\u003eone-third of planned patients\u003c\/strong\u003e as of January 2025.\u003c\/li\u003e\n\u003cli\u003eThe gross proceeds from the October 2025 offering were expected to be approximately \u003cstrong\u003e$150 million\u003c\/strong\u003e, with shares priced at \u003cstrong\u003e$12.00 per share\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOperating expenses for Q3 2025 totaled \u003cstrong\u003e$63.0 million\u003c\/strong\u003e, an increase driven by clinical trial costs for DURAVYU™ Phase 3 trials.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516162171029,"sku":"eypt-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/eypt-vrio-analysis.png?v=1740172565","url":"https:\/\/dcf-model.com\/products\/eypt-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}